Cargando…
Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis
OBJECTIVE: Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce costs and increase treatment capacity (infusion...
Autores principales: | Wallace, Zachary S., Harkness, Tyler, Blumenthal, Kimberly G., Choi, Hyon K., Stone, John H., Walensky, Rochelle P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231514/ https://www.ncbi.nlm.nih.gov/pubmed/32314553 http://dx.doi.org/10.1002/acr2.11133 |
Ejemplares similares
-
Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study
por: Blumenthal, Kimberly G, et al.
Publicado: (2018) -
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019) -
Operating costs and capacity in the airline industry
por: Tsai, Wen-Hsien, et al.
Publicado: (2004) -
Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis
por: Tseng, Chien-Wen, et al.
Publicado: (2020) -
745 Risk of Peripheral Blood Eosinophilia and Hypersensitivity Reactions among Patients Receiving Outpatient Parenteral Antibiotics
por: Blumenthal, Kimberly, et al.
Publicado: (2014)